Biotechnology company Oxigene Inc. said Thursday it reached an agreement with the Food and Drug Administration on the design of a late-stage study for Zybrestat.
Internet NewsShare and Enjoy:These icons link to social bookmarking sites where readers can share and discover new web pages.
Original post by Stephen Heuser, Globe Staff and software by Elliott Back
